EP1442143A4 - DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID) - Google Patents

DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)

Info

Publication number
EP1442143A4
EP1442143A4 EP03709164A EP03709164A EP1442143A4 EP 1442143 A4 EP1442143 A4 EP 1442143A4 EP 03709164 A EP03709164 A EP 03709164A EP 03709164 A EP03709164 A EP 03709164A EP 1442143 A4 EP1442143 A4 EP 1442143A4
Authority
EP
European Patent Office
Prior art keywords
sina
nucleic acid
gene expression
rna interference
short interfering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03709164A
Other languages
English (en)
French (fr)
Other versions
EP1442143A2 (de
Inventor
James Mcswiggen
Leonid Beigelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirna Therapeutics Inc
Original Assignee
Sirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirna Therapeutics Inc filed Critical Sirna Therapeutics Inc
Publication of EP1442143A2 publication Critical patent/EP1442143A2/de
Publication of EP1442143A4 publication Critical patent/EP1442143A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
EP03709164A 2002-02-20 2003-02-18 DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID) Withdrawn EP1442143A4 (de)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US35858002P 2002-02-20 2002-02-20
US358580P 2002-02-20
US36312402P 2002-03-11 2002-03-11
US363124P 2002-03-11
US38678202P 2002-06-06 2002-06-06
US386782P 2002-06-06
US39690502P 2002-07-18 2002-07-18
US396905P 2002-07-18
US40678402P 2002-08-29 2002-08-29
US406784P 2002-08-29
US40837802P 2002-09-05 2002-09-05
US408378P 2002-09-05
US40929302P 2002-09-09 2002-09-09
US409293P 2002-09-09
US44012903P 2003-01-15 2003-01-15
US440129P 2003-01-15
PCT/US2003/004908 WO2003070969A2 (en) 2002-02-20 2003-02-18 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Publications (2)

Publication Number Publication Date
EP1442143A2 EP1442143A2 (de) 2004-08-04
EP1442143A4 true EP1442143A4 (de) 2005-02-16

Family

ID=27761716

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03709164A Withdrawn EP1442143A4 (de) 2002-02-20 2003-02-18 DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)

Country Status (5)

Country Link
EP (1) EP1442143A4 (de)
JP (1) JP2005517452A (de)
AU (1) AU2003213119A1 (de)
CA (1) CA2463595A1 (de)
WO (1) WO2003070969A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
EP2305813A3 (de) 2002-11-14 2012-03-28 Dharmacon, Inc. Funktionale und hyperfunktionale siRNA
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
GB0306148D0 (en) * 2003-03-18 2003-04-23 Milner Jo Regulation of gene expression
JP4505749B2 (ja) * 2003-05-30 2010-07-21 日本新薬株式会社 Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
ATE467679T1 (de) * 2003-12-23 2010-05-15 Santaris Pharma As Oligomere verbindungen zur modulation von bcl-2
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
EP1937280B1 (de) * 2005-09-12 2014-08-27 The Ohio State University Research Foundation Zusammensetzungen zur Therapie von Bcl2-assoziierten Tumoren
EP2487258B1 (de) 2006-01-05 2014-10-01 The Ohio State University Research Foundation Verfahren auf Mikro-RNA-Basis zur Diagnose von Darmkrebs, Bauchspeicheldrüsenkrebs und Magenkrebs
CN101448958A (zh) 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
AU2007296055A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
CA2664271A1 (en) * 2006-11-27 2008-06-12 Enzon Pharmaceuticals, Inc. Polymeric short interfering rna conjugates
JP2010519910A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｂｃｌ２遺伝子の発現を抑制するための核酸化合物およびその使用
WO2008124927A1 (en) * 2007-04-13 2008-10-23 Vincent Research & Consulting Inc. Sirna against thymidylate synthase and uses thereof in cancer treatment regimens
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
EP2310021A4 (de) * 2008-07-10 2012-06-27 Merck Sharp & Dohme Verfahren zur verwendung von zusammensetzungen mit mir-192 und/oder mir-215 zur behandlung von krebs
WO2010021389A1 (ja) * 2008-08-21 2010-02-25 協和発酵キリン株式会社 Ｂｃｌ－２蛋白質の発現を抑制する核酸
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
PT2563920T (pt) 2010-04-29 2017-05-26 Ionis Pharmaceuticals Inc Modulação da expressão de transtirretina
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
US8946187B2 (en) 2010-11-12 2015-02-03 The Ohio State University Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
EP2790735A4 (de) 2011-12-13 2015-12-09 Ohio State Innovation Foundation Verfahren und zusammensetzungen im zusammenhang mit mir-21 und mir-29a, exosomerhemmung und krebsmetastasen
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
EP3254700B1 (de) * 2012-03-04 2019-10-23 Bonac Corporation Mikro-rna-inhibitor
US20150259690A1 (en) 2012-10-05 2015-09-17 Bioneer Corporation Amphiregulin-specific double-helical oligo-rna, double-helical oligo-rna structure comprising double-helical oligo-rna, and composition for preventing or treating respiratory diseases containing same
CN104884637A (zh) * 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
US10208309B2 (en) 2014-04-04 2019-02-19 Bioneer Corporation Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
KR101993377B1 (ko) * 2017-07-20 2019-06-26 (주)큐리진 Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산
CN113038956A (zh) * 2018-12-05 2021-06-25 日东电工株式会社 癌处置用RNAi分子
JPWO2020196736A1 (de) * 2019-03-28 2020-10-01

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044895A1 (de) * 1999-01-30 2000-08-03 Roland Kreutzer Verfahren und medikament zur hemmung der expression eines vorgegebenen gens
WO2002010374A2 (en) * 2000-08-02 2002-02-07 University Of Southern California Gene silencing using mrna-cdna hybrids
WO2002055692A2 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044895A1 (de) * 1999-01-30 2000-08-03 Roland Kreutzer Verfahren und medikament zur hemmung der expression eines vorgegebenen gens
WO2002010374A2 (en) * 2000-08-02 2002-02-07 University Of Southern California Gene silencing using mrna-cdna hybrids
WO2002055692A2 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CIOCA DANIEL P ET AL: "RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.", CANCER GENE THERAPY, vol. 10, no. 2, February 2003 (2003-02-01), pages 125 - 133, XP002293680, ISSN: 0929-1903 *
ELBASHIR S M ET AL: "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 20, no. 23, 3 December 2001 (2001-12-03), pages 6877 - 6888, XP002225998, ISSN: 0261-4189 *
FUTAMI TAKASHI ET AL: "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2.", NUCLEIC ACIDS RESEARCH. SUPPLEMENT (2001) 2002, no. 2, 2002, pages 251 - 252, XP002264267 *
KUMAR SHAJI ET AL: "Bcl-2 Over-Expression Results in Decreased Measles Virus Mediated Cytotoxicity in Lymphoma Cell Lines.", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 2268, XP009042070, ISSN: 0006-4971 *
MIYAGISHI M ET AL: "U6 PROMOTER-DRIVEN SIRNAS WITH FOUR URIDINE 3' OVERHANGS EFFICIENTLY SUPPRESS TARGETED GENE EXPRESSION IN MAMMALIAN CELLS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 19, no. 5, May 2002 (2002-05-01), pages 497 - 500, XP001153719, ISSN: 1087-0156 *
NEUREITER D ET AL: "Growth inhibition of pancreatic cancer in nude mice by targeting bcl2-suppression with specific short interfering RNA molecules.", PATHOLOGY RESEARCH AND PRACTICE, vol. 199, no. 4, 2003, & 87TH MEETING OF THE GERMAN SOCIETY OF PATHOLOGY AND 23RD MEETING OF THE GERMAN SOCIETY OF CYTOLOGY; BAMBERG, GERMANY; JUNE 11-14, 2003, pages 257, XP009042053, ISSN: 0344-0338 *
OPALINSKA JOANNA B ET AL: "A Rational Approach to Nucleic Acid Based Targeting of RNA Molecules Using Self-Quenching Reporter Molecules (SQRM).", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 726, XP009042069, ISSN: 0006-4971 *
PARRISH S ET AL: "Functional anatomy of a dsRNA trigger: Differential requirement for the two trigger strands in RNA interference", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 6, no. 5, November 2000 (2000-11-01), pages 1077 - 1087, XP002226298, ISSN: 1097-2765 *

Also Published As

Publication number Publication date
WO2003070969A2 (en) 2003-08-28
AU2003213119A1 (en) 2003-09-09
CA2463595A1 (en) 2003-08-28
EP1442143A2 (de) 2004-08-04
WO2003070969A3 (en) 2004-01-08
JP2005517452A (ja) 2005-06-16

Similar Documents

Publication Publication Date Title
EP1442143A4 (de) DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)
EP1572128A4 (de) RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER HIV-GEN-EXPRESSION MIT KURZINTERFERENZ-NUKLEINSÄURE (siNA)
HK1086036A1 (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
AU2003216255A8 (en) Rna interference mediated inhibition of mdr p-glycoprotein gene expression using short interfering nucleic acid (sina)
AU2003210895A8 (en) Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
EP1476457A4 (de) DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER EXPRESSION DES GENS DER PROTEIN-TYROSINPHOSPHATASE-1B (PTP-1B) UNTER VERWENDUNG VON SiNA (SHORT INTERFERING NUCLEIC ACID)
EP1478730A4 (de) RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER EXPRESSION DER GENE FÜR DIE TNF- UND TNF-REZEPTOR-SUPERFAMILIEN UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)
EP1521768A4 (de) Durch rna-interferenz vermittelte hemmung des vaskulären endothelischen wachstumsfaktors und der expression des gens für den rezeptor des vaskulären endothelischen wachstumsfaktors unter verwendung von sina (short interfering nucleic acid)
AU2003211058A8 (en) Rna interference mediated target discovery and target validation using short interfering nucleic acid (sina)
AU2003219833A8 (en) Rna interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (sina)
AU2003213054A8 (en) Rna interference mediated inhibition of polycomb group protein ezh2 gene expression using short interfering nucleic acid (sina)
AU2003297474A8 (en) Methods of inhibiting gene expression by rna interference
AU2003287254A1 (en) Inhibition of gene expression using rna interfering agents
EP1432725A4 (de) Rna-interferenz-vermittelte inhibierung von telomerasegenexpression mit kurzer interferierender nukleinsäure (sina)
GB2406568B (en) RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003213057A8 (en) Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
EP1463842A4 (de) Rna-interferenz-vermittelte hemmung der expression des gens für proteinkinase c-alpha (pkc-alpha) unter verwendung von sina (short interfering nucleic acid)
AU2003220136A8 (en) Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina)
AU2003219781A1 (en) RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1499628A4 (de) Rna-interferenz-vermittelte hemmung der expression des stearoyl-coa-desaturase (scd)-gens unter verwendung von sina (short interfering nucleic acid)
EP1495041A4 (de) DURCH RNA-INTERFERENZ VERMITTELTE INHIBIERUNG DER GENEXPRESSION VON G72 UND D-AMINOSÄUREOXIDASE (DAAO) UNTER VERWENDUNG KURZER INTERFERIERENDER NUKLEINSÄURE (siNA)
EP1652917A4 (de) Zur hemmung der expression des klf5-gens fähige rna
GB0519282D0 (en) RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
GB0511689D0 (en) RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003219818A8 (en) Rna interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (sina)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040505

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20050105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071018